En vivo
Clinical OMICsTARGA Imager Enables High-Resolution Imaging of Neurodevelopmental ModelsBioPharma DiveRoche stakes $700M on Nurix’s protein-degrading drugClinical OMICsSignatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care PathwayEndpoints NewsGoHealth files for bankruptcy, as Medicare Advantage insurers pull backAgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.stBioPharma DiveTango data add to growing momentum for pancreatic cancer drugsBioWorldAppointments and advancements for June 8, 2026BioWorldFinancings for June 8, 2026BioWorldIn the clinic for June 8, 2026BioWorldOther news to note for June 8, 2026BioWorldRegulatory actions for June 8, 2026Thermo FisherThermo Fisher Scientific Introduces New Mass Spectrometry Platforms and AI Software - Clinical Lab Products
eLife 23 mar 2026

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in <i>FGFR2</i>-amplified gastric cancer

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2 -amplified gastric cancer

Original
Contenido no disponible. Consulta la fuente original.